Taste Alterations in Cancer Patients Receiving Chemotherapy: A Neglected Side Effect?

Author:

Zabernigg August1,Gamper Eva-Maria2,Giesinger Johannes M.2,Rumpold Gerhard2,Kemmler Georg2,Gattringer Klaus1,Sperner-Unterweger Barbara2,Holzner Bernhard2

Affiliation:

1. a Department of Internal Medicine, Kufstein County Hospital (Teaching Hospital of Innsbruck Medical University), Kufstein, Austria

2. b Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria

Abstract

Abstract Learning Objectives After completing this course, the reader will be able to: Evaluate the effect of various chemotherapy regimens on taste alterations.Investigate the effect of chemotherapy-induced taste alterations on patients and use available dietary approaches such as taste enhancement and substitution of proteins and nutrients of avoided food to improve quality of life. CME This article is available for continuing medical education credit at CME.TheOncologist.com. Background. Taste alterations (TAs) are a frequent but under-recognized treatment side effect in cancer patients undergoing chemotherapy (CT). CT regimens with different toxicity profiles may vary in their impact on TAs, but research on this topic is lacking. This study assesses the prevalence of TAs and their relation to sociodemographic and clinical variables, especially CT regimens. Furthermore, the association between TAs and quality of life (QOL) is investigated. Patients and Methods. TAs and QOL data were collected longitudinally in 197 cancer patients (lung cancer, 54.3%; pancreatic cancer, 19.3%; colorectal cancer, 26.4%; age, 65.2 ±10.4 years; male, 57.4%) who were receiving CT at the Department of Internal Medicine at Kufstein County Hospital, giving rise to a total of 1,024 assessment times. Patients completed the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire and two additional questions taken from the EORTC item bank concerning TAs. Statistical analyses were performed using mixed-effect models. Results. The study showed that the prevalence of TAs in chemotherapy patients is alarmingly high (69.9%). There were clear differences in TA scores among treatment groups: patients receiving irinotecan reported significantly more TAs than patients in other treatment groups; patients receiving a combination of gemcitabine and a platinum agent reported the lowest TAs. Additionally, significant associations between TAs and several QOL dimensions were found, especially with appetite loss and fatigue. Conclusion. The high prevalence of TAs and their impact on QOL in CT patients underscore the urgent need for increased attention to this side effect, both in research and in clinical practice.

Funder

Austrian National Bank

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference31 articles.

1. Perception of chemotherapy side effects cancer versus noncancer patients;Lindley;Cancer Pract,1999

2. Self-reported taste and smell changes during cancer chemotherapy;Bernhardson;Support Care Cancer,2008

3. Drug-induced taste and smell disorders;Henkin;Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction. Drug Saf,1994

4. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients;Jensen;Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol,2008

5. Abnormalities of taste sensation in cancer patients;DeWys;Cancer,1975

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3